Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 9

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 9
---
     |  71 |     | May 2018        |     | Audit (Chair),                               
 Compensation                                 |
| Peter Hirth, Ph.D.                                             |     |  73 |     | September 2016  |     | Compensation,                                
 Nominating and Corporate Governance          |
| Mai-Britt Zocca, Ph.D.                                         |     |  57 |     | May 2021        |     | —                                            |

* For each director other than Dr. Zocca and Mr. Smith, the date provided refers to the date such director began serving on the board of directors of our wholly owned subsidiary, IO Biotech ApS. Each of our directors other than Dr. Zocca and Mr. Smith began serving on our board of directors in October 2021 in connection with our corporate reorganization prior to our initial public offering. Additional biographical descriptions of the nominees and continuing directors are set forth in the text below. These descriptions include the experience, qualifications, qualities and skills that led to the conclusion that each director should serve as a member of our board of directors at this time.

<div align='center'>6</div>

Board Nominee – Class I Director

David V. Smith, M.B.A.– Mr. Smith has served as a member of our board of directors since March 2022. Mr. Smith most recently served as Executive Vice President and Chief Financial Officer at Five Prime Therapeutics, Inc., a publicly traded company focused on discovering and developing novel immuno-oncology protein therapeutics. He served in this role from November 2018 until Five Prime Therapeutics was acquired by Amgen in April 2021. From May 2012 until its acquisition by Thermo Fisher Scientific Inc. in March 2018, Mr. Smith served as Chief Operating Officer of IntegenX. Previously, he served as chief financial officer at Thoratec, Chiron and Anergen. He has also held finance positions with Genentech, Inc., Syntex, and IBM. Mr. Smith is currently the Lead Independent Director of Codexis, Inc., a public biotechnology company, and the Chair of the Audit Committee of Neurelis, Inc., a private biotechnology company. Previously, he served as chair of the Audit Committee and a director of OncoGenex Pharmaceuticals, Inc. and Perlegen Sciences. Mr. Smith holds a B.A. in economics and history from Willamette University and an M.B.A. from Golden Gate University.